XFOR - X4 Pharmaceuticals: PDUFA Excitement Ahead

2024-04-15 18:21:52 ET

Summary

• X4 Pharmaceuticals, Inc. is awaiting an FDA decision on its lead molecule mavorixafor for the treatment of WHIM syndrome.
• Mavorixafor is a powerful immune system booster with potential in treating rare immunodeficiency.
• X4's financial position is challenging, with increasing expenses and a significant accumulated deficit.

This is my first article discussing X4 Pharmaceuticals, Inc. ( XFOR ) a development-stage pharma. Its NDA for its lead molecule mavorixafor in treatment of WHIM (warts, hypogammaglobulinemia, infections, myelokathexis) is waiting on an FDA decision at the end of April....

For further details see: